Aligos Therapeutics Closes $125M Series B Financing
SOUTH SAN FRANCISCO, Calif. January 10, 2020 – Aligos Therapeutics, Inc., a preclinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), today announced the closing of an oversubscribed $125M Series B equity financing round ledRead More
Aligos Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif. January 7, 2020 – Aligos Therapeutics, a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC), today announced that CEO Lawrence Blatt, Ph.D., MBA, will present at the 38th Annual J.P.Read More
Aligos Therapeutics Presents Combination-Based Approach for Treating Chronic Hepatitis B (CHB) at HEP DART 2019
Aligos Therapeutics Presents Combination-Based Approach for Treating Chronic Hepatitis B (CHB) at HEP DART 2019 Oral Presentation on Combination Therapy Targeting CHB SOUTH SAN FRANCISCO, Calif. December 10, 2019 – Aligos Therapeutics, a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB),Read More
Aligos Therapeutics Welcomes Kathleen Sereda Glaub to its Board of Directors
Aligos Therapeutics Welcomes Kathleen Sereda Glaub to its Board of Directors SOUTH SAN FRANCISCO, Calif. November 25, 2019 – Aligos Therapeutics, Inc. (Aligos), a biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC), today announced the appointmentRead More
Aligos Therapeutics Presents NASH Asset Development Update atThe Liver Meeting® 2019
Aligos Therapeutics Presents NASH Asset Development Update atThe Liver Meeting® 2019 SOUTH SAN FRANCISCO, Calif., November 11, 2019 – Aligos Therapeutics, Inc. (Aligos), a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC), highlighted promisingRead More
Aligos Therapeutics Presents Strong Chronic Hepatitis B Drug Candidate Portfolio atThe Liver Meeting® 2019
Aligos Therapeutics Presents Strong Chronic Hepatitis B Drug Candidate Portfolio atThe Liver Meeting® 2019 Poster presentations demonstrate early preclinical successes of strategically designed, complementary therapies aimed at effecting a functional cure in chronic hepatitis B  SOUTH SAN FRANCISCO, Calif. November 8, 2019 – Aligos Therapeutics, Inc. (Aligos), a pre-clinical stage biotechnology company focused on theRead More
Aligos Therapeutics to Present Multiple Posters During The Liver Meeting® 2019
Aligos Therapeutics to Present Multiple Posters During The Liver Meeting® 2019 Posters to highlight recent advances for the company’s development-stage products for HBV and NASH SOUTH SAN FRANCISCO, Calif. October 29, 2019 – Aligos Therapeutics, Inc. (Aligos), a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections,Read More
Aligos Therapeutics Appoints Industry Veteran Matthew W. McClure, M.D., as Executive Vice President, Chief Medical Officer
Aligos Therapeutics Appoints Industry Veteran Matthew W. McClure, M.D., as Executive Vice President, Chief Medical Officer South San Francisco, California, October 14, 2019 – Aligos Therapeutics, Inc.(Aligos), a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B(CHB), nonalcoholic steatohepatitis(NASH), and hepatocellular carcinoma(HCC),today announcedRead More